This bulletin reviews the evidence for angiotensin converting enzyme inhibitors (ACEI), A2RAs and a combination of both agents. The strength of the evidence is then compared for indications including hypertension, heart failure, diabetes and chronic kidney disease.
The frequency of cough is also considered for both drug classes. Data from the ONTARGET study are used to produce a patient decision aid that summarises the small benefit of A2RAs in reduction of cough. The levels of prescribing of both drug classes in primary and secondary care settings and cost savings are projected based on an increased proportional use of ACEIs.
Action: Clinicians who prescribed ACEIs or A2RAs will find this bulletin useful and informative.